Compile Data Set for Download or QSAR
Report error Found 297 Enz. Inhib. hit(s) with all data for entry = 12405
TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Korea Reserarch Institute of Chemical Technology

US Patent
LigandPNGBDBM700922(N-(2-((2,5-dichloropyrimidin-4- yl)amino)-6-methyl...)
Affinity DataIC50: 0.100nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Human)
Korea Reserarch Institute of Chemical Technology

US Patent
LigandPNGBDBM700904(N-(5-amino-4-methoxy-2- (methyl(2-(piperidin-1- yl...)
Affinity DataIC50: 0.300nMAssay Description:The activity of the compounds of the present invention against HER mutant enzymes was measured using the HTRF system purchased by Cisbio as follows. ...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Human)
Korea Reserarch Institute of Chemical Technology

US Patent
LigandPNGBDBM700927(N-(2-((2,5-dichloropyrimidin-4- yl)amino)-5-methyl...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against HER mutant enzymes was measured using the HTRF system purchased by Cisbio as follows. ...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Human)
Korea Reserarch Institute of Chemical Technology

US Patent
LigandPNGBDBM700928(N-(2-((2,5-dichloropyrimidin-4- yl)amino)-5- methy...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against HER mutant enzymes was measured using the HTRF system purchased by Cisbio as follows. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Human)
Korea Reserarch Institute of Chemical Technology

US Patent
LigandPNGBDBM700974(N-(5-amino-4-methoxy-2- (methyl(2- morpholinoethyl...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against HER mutant enzymes was measured using the HTRF system purchased by Cisbio as follows. ...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Korea Reserarch Institute of Chemical Technology

US Patent
LigandPNGBDBM700796(N1-(2,5-dichloropyrimidin-4- yl)benzen-1,2-diamine...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Human)
Korea Reserarch Institute of Chemical Technology

US Patent
LigandPNGBDBM700933(methyl 2-chloro-4-((1- (methylsulfonyl)-1,2,3,4- t...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against HER mutant enzymes was measured using the HTRF system purchased by Cisbio as follows. ...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Korea Reserarch Institute of Chemical Technology

US Patent
LigandPNGBDBM700794(2,5-dichloro-N-(2- nitrophenyl)pyrimidin-4-amine |...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Human)
Korea Reserarch Institute of Chemical Technology

US Patent
LigandPNGBDBM700929(N-(2,5-dichloropyrimidin-4-yl)-1- (methylsulfonyl)...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against HER mutant enzymes was measured using the HTRF system purchased by Cisbio as follows. ...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Korea Reserarch Institute of Chemical Technology

US Patent
LigandPNGBDBM700887(N-(2-((2-chloropyrimidin-4- yl)amino)phenyl)benzen...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Korea Reserarch Institute of Chemical Technology

US Patent
LigandPNGBDBM700885(N-(2-((2,5-dichloropyrimidin-4- yl)amino)phenyl)pr...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Human)
Korea Reserarch Institute of Chemical Technology

US Patent
LigandPNGBDBM700951(N-(5-amino-4-methoxy-2-(2- (piperidin-1- yl)ethoxy...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against HER mutant enzymes was measured using the HTRF system purchased by Cisbio as follows. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Korea Reserarch Institute of Chemical Technology

US Patent
LigandPNGBDBM700884(N-(2-((2,5-dichloropyrimidin-4- yl)amino)phenyl)et...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-763,'FHEA',764-1210](Human)
Korea Reserarch Institute of Chemical Technology

US Patent
LigandPNGBDBM700884(N-(2-((2,5-dichloropyrimidin-4- yl)amino)phenyl)et...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Korea Reserarch Institute of Chemical Technology

US Patent
LigandPNGBDBM700891(N-(2-((2-chloropyrimidin-4- yl)amino)phenyl)ethane...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Korea Reserarch Institute of Chemical Technology

US Patent
LigandPNGBDBM700889(N-(2-((2-chloropyrimidin-4- yl)amino)phenyl)propan...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Human)
Korea Reserarch Institute of Chemical Technology

US Patent
LigandPNGBDBM700942(tert-butyl (5-acrylamido-2- methoxy-4-(methyl(2- m...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against HER mutant enzymes was measured using the HTRF system purchased by Cisbio as follows. ...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Korea Reserarch Institute of Chemical Technology

US Patent
LigandPNGBDBM700878(tert-butyl (4-((2- (dimethylamino)ethyl)(methyl) a...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-763,'FHEA',764-1210](Human)
Korea Reserarch Institute of Chemical Technology

US Patent
LigandPNGBDBM700878(tert-butyl (4-((2- (dimethylamino)ethyl)(methyl) a...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Korea Reserarch Institute of Chemical Technology

US Patent
LigandPNGBDBM700865(tert-butyl (4-fluoro-2-methoxy-5- nitrophenyl)carb...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Korea Reserarch Institute of Chemical Technology

US Patent
LigandPNGBDBM700843(N-(2-((2,5-dichloropyrimidin-4- yl)amino)phenyl)pr...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Human)
Korea Reserarch Institute of Chemical Technology

US Patent
LigandPNGBDBM700949(N-(5-amino-4-methoxy-2- (methyl(2-(4-methylpiperaz...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against HER mutant enzymes was measured using the HTRF system purchased by Cisbio as follows. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Korea Reserarch Institute of Chemical Technology

US Patent
LigandPNGBDBM700883(N-(2-((2,5-dichloropyrimidin-4- yl)amino)phenyl)-4...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Human)
Korea Reserarch Institute of Chemical Technology

US Patent
LigandPNGBDBM700950(N-(5-amino-4-methoxy-2-(2- morpholinoethoxy)phenyl...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against HER mutant enzymes was measured using the HTRF system purchased by Cisbio as follows. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Human)
Korea Reserarch Institute of Chemical Technology

US Patent
LigandPNGBDBM700946(N-(6-((2,5-dichloropyrimidin-4- yl)amino)quinoxali...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against HER mutant enzymes was measured using the HTRF system purchased by Cisbio as follows. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Korea Reserarch Institute of Chemical Technology

US Patent
LigandPNGBDBM700880(tert-butyl (5-acrylamido-4-((2- (dimethylamino)eth...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Human)
Korea Reserarch Institute of Chemical Technology

US Patent
LigandPNGBDBM700944(N-(2,5-dichloropyrimidin-4-yl)-1- (methylsulfonyl)...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against HER mutant enzymes was measured using the HTRF system purchased by Cisbio as follows. ...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Korea Reserarch Institute of Chemical Technology

US Patent
LigandPNGBDBM700903(N-(5-amino-4-methoxy-2-(2- (pyrrolidin-1- yl)ethox...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-763,'FHEA',764-1210](Human)
Korea Reserarch Institute of Chemical Technology

US Patent
LigandPNGBDBM700903(N-(5-amino-4-methoxy-2-(2- (pyrrolidin-1- yl)ethox...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Korea Reserarch Institute of Chemical Technology

US Patent
LigandPNGBDBM700902(N-(5-amino-4-methoxy-2- (methyl(2-(pyrrolidin-1- y...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-763,'FHEA',764-1210](Human)
Korea Reserarch Institute of Chemical Technology

US Patent
LigandPNGBDBM700902(N-(5-amino-4-methoxy-2- (methyl(2-(pyrrolidin-1- y...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Korea Reserarch Institute of Chemical Technology

US Patent
LigandPNGBDBM700901(N-(2-((2-chloro-5-methylpyrimidin- 4-yl)amino) phe...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Korea Reserarch Institute of Chemical Technology

US Patent
LigandPNGBDBM700907(benzyl (2-((2-acrylamido-4-amino- 5- methoxyphenyl...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-763,'FHEA',764-1210](Human)
Korea Reserarch Institute of Chemical Technology

US Patent
LigandPNGBDBM700907(benzyl (2-((2-acrylamido-4-amino- 5- methoxyphenyl...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Korea Reserarch Institute of Chemical Technology

US Patent
LigandPNGBDBM700906(benzyl (2-((2-acrylamido-4-((5- chloro-4-((2- (met...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-763,'FHEA',764-1210](Human)
Korea Reserarch Institute of Chemical Technology

US Patent
LigandPNGBDBM700906(benzyl (2-((2-acrylamido-4-((5- chloro-4-((2- (met...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Korea Reserarch Institute of Chemical Technology

US Patent
LigandPNGBDBM700905(benzyl (2-((2-acrylamido-4-amino- 5-methoxyphenyl)...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-763,'FHEA',764-1210](Human)
Korea Reserarch Institute of Chemical Technology

US Patent
LigandPNGBDBM700905(benzyl (2-((2-acrylamido-4-amino- 5-methoxyphenyl)...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Korea Reserarch Institute of Chemical Technology

US Patent
LigandPNGBDBM700904(N-(5-amino-4-methoxy-2- (methyl(2-(piperidin-1- yl...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-763,'FHEA',764-1210](Human)
Korea Reserarch Institute of Chemical Technology

US Patent
LigandPNGBDBM700904(N-(5-amino-4-methoxy-2- (methyl(2-(piperidin-1- yl...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Korea Reserarch Institute of Chemical Technology

US Patent
LigandPNGBDBM700895(N-(2-((2-chloro-5-fluoropyrimidin- 4-yl)amino) phe...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Korea Reserarch Institute of Chemical Technology

US Patent
LigandPNGBDBM700894(N-(2-((2-chloro-5-fluoropyrimidin- 4-yl)amino)phen...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Korea Reserarch Institute of Chemical Technology

US Patent
LigandPNGBDBM700892(N-(2-((2-chloro-5-fluoropyrimidin- 4-yl)amino) phe...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Korea Reserarch Institute of Chemical Technology

US Patent
LigandPNGBDBM700898(N-(2-((2-chloro-5-methylpyrimidin- 4-yl)amino)phen...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-763,'FHEA',764-1210](Human)
Korea Reserarch Institute of Chemical Technology

US Patent
LigandPNGBDBM700898(N-(2-((2-chloro-5-methylpyrimidin- 4-yl)amino)phen...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Korea Reserarch Institute of Chemical Technology

US Patent
LigandPNGBDBM700897(N-(2-((2-chloro-5-methylpyrimidin- 4-yl)amino) phe...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Korea Reserarch Institute of Chemical Technology

US Patent
LigandPNGBDBM700896(N-(2-((2-chloro-5-fluoropyrimidin- 4-yl)amino)phen...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Korea Reserarch Institute of Chemical Technology

US Patent
LigandPNGBDBM700919(N-(2-((2,5-dichloropyrimidin-4- yl)amino)-6- methy...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-763,'FHEA',764-1210](Human)
Korea Reserarch Institute of Chemical Technology

US Patent
LigandPNGBDBM700919(N-(2-((2,5-dichloropyrimidin-4- yl)amino)-6- methy...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

TargetEpidermal growth factor receptor [1-18,20-1210](Human)
Korea Reserarch Institute of Chemical Technology

US Patent
LigandPNGBDBM700918(N-(2-chloro-6-((2,5- dichloropyrimidin-4- yl)amino...)
Affinity DataIC50: 1nMAssay Description:The activity of the compounds of the present invention against EGFR mutant enzymes was measured using the HTRF system purchased from Cisbio as follow...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
2/23/2025
Entry Details
US Patent

Displayed 1 to 50 (of 297 total ) | Next | Last >>
Jump to: